The Zhitong Finance App learned that on Friday, BioNTech (BNTX.US) opened lower, with the biggest intraday decline of more than 9%. As of press release, the decline had narrowed to 6.79% to $103.84. According to the news, the company announced the termination of the Phase 2 Cevumeran cancer immunotherapy trial. BioNTech SE announced that it has decided to discontinue phase 2 clinical trials (BNT122-01; nct04486378), a study evaluating ongoing individualized mRNA cancer immunotherapy autogene cevumeran (BNT122/RO7198457) as an adjuvant monotherapy to treat stage II (high risk) or stage III colorectal cancer (CRC) patients with positive circulating tumor DNA (ctDNA) who have been surgically removed. Autogene Cevumeran was jointly developed by BioNTech and Genetec, a member of the Roche Group. The decision to discontinue the clinical trial was made after consultation with Genetec.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.